Tidal Investments LLC Sells 792 Shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

Tidal Investments LLC cut its holdings in shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) by 3.7% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 20,877 shares of the specialty pharmaceutical company’s stock after selling 792 shares during the quarter. Tidal Investments LLC’s holdings in Jazz Pharmaceuticals were worth $2,326,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the business. Wealth Enhancement Advisory Services LLC raised its holdings in Jazz Pharmaceuticals by 27.6% in the 2nd quarter. Wealth Enhancement Advisory Services LLC now owns 3,551 shares of the specialty pharmaceutical company’s stock valued at $379,000 after acquiring an additional 768 shares in the last quarter. Envestnet Portfolio Solutions Inc. lifted its position in Jazz Pharmaceuticals by 13.9% during the second quarter. Envestnet Portfolio Solutions Inc. now owns 2,753 shares of the specialty pharmaceutical company’s stock worth $294,000 after purchasing an additional 335 shares during the period. Blue Trust Inc. grew its stake in Jazz Pharmaceuticals by 24.5% during the second quarter. Blue Trust Inc. now owns 1,307 shares of the specialty pharmaceutical company’s stock worth $139,000 after buying an additional 257 shares in the last quarter. Hennion & Walsh Asset Management Inc. increased its holdings in Jazz Pharmaceuticals by 16.6% in the 2nd quarter. Hennion & Walsh Asset Management Inc. now owns 29,447 shares of the specialty pharmaceutical company’s stock valued at $3,143,000 after buying an additional 4,183 shares during the period. Finally, Fifth Third Wealth Advisors LLC acquired a new position in shares of Jazz Pharmaceuticals in the 2nd quarter valued at approximately $206,000. 89.14% of the stock is currently owned by institutional investors and hedge funds.

Jazz Pharmaceuticals Stock Down 0.5 %

NASDAQ:JAZZ opened at $123.04 on Monday. Jazz Pharmaceuticals plc has a one year low of $99.06 and a one year high of $134.17. The company has a debt-to-equity ratio of 1.46, a current ratio of 4.26 and a quick ratio of 3.74. The company has a market cap of $7.44 billion, a PE ratio of 17.33, a P/E/G ratio of 1.02 and a beta of 0.57. The firm’s 50 day simple moving average is $117.39 and its 200 day simple moving average is $112.22.

Insider Activity

In related news, CEO Bruce C. Cozadd sold 2,000 shares of the firm’s stock in a transaction on Monday, December 2nd. The stock was sold at an average price of $121.17, for a total transaction of $242,340.00. Following the completion of the transaction, the chief executive officer now directly owns 427,025 shares of the company’s stock, valued at $51,742,619.25. This trade represents a 0.47 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Neena M. Patil sold 3,700 shares of Jazz Pharmaceuticals stock in a transaction dated Friday, November 8th. The stock was sold at an average price of $123.41, for a total value of $456,617.00. Following the transaction, the executive vice president now directly owns 33,048 shares in the company, valued at $4,078,453.68. The trade was a 10.07 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 6,753 shares of company stock valued at $816,289. Insiders own 4.20% of the company’s stock.

Wall Street Analysts Forecast Growth

JAZZ has been the topic of several analyst reports. HC Wainwright reiterated a “buy” rating and set a $200.00 price target on shares of Jazz Pharmaceuticals in a research report on Friday, November 22nd. Needham & Company LLC reiterated a “buy” rating and issued a $207.00 price target on shares of Jazz Pharmaceuticals in a research note on Thursday. TD Cowen lowered their price target on Jazz Pharmaceuticals from $200.00 to $195.00 and set a “buy” rating for the company in a report on Thursday, November 7th. JPMorgan Chase & Co. raised their price objective on Jazz Pharmaceuticals from $190.00 to $202.00 and gave the company an “overweight” rating in a research note on Monday, August 19th. Finally, Robert W. Baird boosted their target price on Jazz Pharmaceuticals from $154.00 to $162.00 and gave the stock an “outperform” rating in a research note on Monday, November 18th. Two equities research analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $177.00.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.